Akero Therapeutics Inc (AKRO)
19.72
+0.78
(+4.15%)
USD |
NASDAQ |
Apr 26, 16:00
19.72
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Enterprise Value: 780.13M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 780.13M |
| April 24, 2024 | 871.83M |
| April 23, 2024 | 922.85M |
| April 22, 2024 | 908.37M |
| April 19, 2024 | 906.30M |
| April 18, 2024 | 889.07M |
| April 17, 2024 | 964.22M |
| April 16, 2024 | 977.32M |
| April 15, 2024 | 972.49M |
| April 12, 2024 | 1.004B |
| April 11, 2024 | 980.77M |
| April 10, 2024 | 984.90M |
| April 09, 2024 | 1.112B |
| April 08, 2024 | 1.070B |
| April 05, 2024 | 1.076B |
| April 04, 2024 | 1.059B |
| April 03, 2024 | 1.073B |
| April 02, 2024 | 1.087B |
| April 01, 2024 | 1.135B |
| March 28, 2024 | 1.217B |
| March 27, 2024 | 1.161B |
| March 26, 2024 | 1.157B |
| March 25, 2024 | 1.141B |
| March 22, 2024 | 1.208B |
| March 21, 2024 | 1.263B |
| Date | Value |
|---|---|
| March 20, 2024 | 1.212B |
| March 19, 2024 | 1.257B |
| March 18, 2024 | 1.326B |
| March 15, 2024 | 1.374B |
| March 14, 2024 | 1.362B |
| March 13, 2024 | 1.403B |
| March 12, 2024 | 1.437B |
| March 11, 2024 | 1.496B |
| March 08, 2024 | 1.625B |
| March 07, 2024 | 1.213B |
| March 06, 2024 | 1.164B |
| March 05, 2024 | 1.193B |
| March 04, 2024 | 1.224B |
| March 01, 2024 | 1.041B |
| February 29, 2024 | 994.42M |
| February 28, 2024 | 1.008B |
| February 27, 2024 | 1.012B |
| February 26, 2024 | 820.46M |
| February 23, 2024 | 901.53M |
| February 22, 2024 | 824.77M |
| February 21, 2024 | 815.29M |
| February 20, 2024 | 680.36M |
| February 16, 2024 | 639.66M |
| February 15, 2024 | 668.66M |
| February 14, 2024 | 687.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.76M
Minimum
Oct 27 2023
2.828B
Maximum
Jun 13 2023
855.29M
Average
636.46M
Median
Jul 12 2021
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.349B |
| 89bio Inc | 231.53M |
| Viking Therapeutics Inc | 6.630B |
| Eli Lilly and Co | 711.57B |
| Ionis Pharmaceuticals Inc | 5.050B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.19M |
| Total Expenses (Quarterly) | 61.87M |
| EPS Diluted (Quarterly) | -1.02 |
| Earnings Yield | -14.61% |